On Wednesday, pharmaceutical giant Eli Lilly sued four prominent telehealth companies that offer more affordable, off-brand versions of its patented best-selling GLP-1 medications Mounjaro and Zepbound. The lawsuits target four telehealth brands, Mochi Health, Fella & Delilah Health, Willow Health, and Henry Meds. In response to general questions about its business practices, Mochi Health said in a statement that it offers compounded GLP-1 medications that are “customized for medical necessity." Fella & Delilah Health, Willow Health, and Henry Meds did not respond to questions about its business practices in time for publication. (Novo Nordisk’s competing GLP-1 medications, Ozempic and Wegovy, also went into shortage in 2022.)